Clot block.

There’s already an oral factor Xa inhibitor for secondary prevention of malignant thrombosis, and now we have one for primary prevention. In the phase 3 AVERT trial, higher risk ambulatory patients receiving chemo and randomized to apixaban had less than half the rate of thrombosis as those randomized to placebo. | Carrier, N Engl J Med 2018


Popular Posts